Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

26.31 -1.10 (-4.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ultragenyx Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
FDA Delays Approval For Ultragenyx's Gene Therapy, But Not A Dealbreaker, Says Analyst
Ultragenyx's UX111 gene therapy faces FDA delay due to facility issues; analysts adjust price targets amid uncertain resubmission timeline. 
Via Benzinga
Ultragenyx Pharma Takes Another Hit As FDA Slaps Its Gene Therapy With A Rejection
The company has a bigger problem than just the FDA rejection, says one analyst. It's timeline to profitability is now longer. 
Via Investor's Business Daily
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
Via Benzinga
Earnings Scheduled For May 6, 2025
Via Benzinga
Ultragenyx Pharmaceutical's Earnings: A Preview
Via Benzinga
Breaking Down Ultragenyx Pharmaceutical: 7 Analysts Share Their Views
Via Benzinga
Market Monitor News July 11 BMO (Airline stocks UP - Ultragenyx Pharmaceuticals DOWN)
Investors shrug off tariff drama as earnings, chip euphoria, and airline optimism steal the show. 
Via Chartmill
Topics World Trade
Breaking Down Ultragenyx Pharmaceutical: 4 Analysts Share Their Views
Via Benzinga
Let's take a look at the stocks that are in motion in today's session.
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Down Over 2%; Delta Air Lines Posts Upbeat Earnings
Via Benzinga
Which stocks are experiencing notable movement on Thursday?
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
US Stocks Mixed; Initial Jobless Claims Fall
Via Benzinga
Ultragenyx, Mereo Hammered For Their Surprise Miss In Brittle Bone Disease
The study will continue onto a third and final analysis toward the end of the year. 
Via Investor's Business Daily
Thursday's session: gap up and gap down stocks
Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win
Ultragenyx shares fall after Phase 3 study misses interim target, but analysts remain positive ahead of final OI data expected later this year. 
Via Benzinga
Get insights into the top gainers and losers of Thursday's pre-market session.
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why WK Kellogg Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Ultragenyx, Mereo Sink After Hours As Bone Drug Trial Continues Without Early Stop; Retail Traders Feel Selloff Is Overdone
The companies now expect final data from the Orbit and Cosmic studies by the end of the year. 
Via Stocktwits
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
What's going on in today's after hours session
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
Ultragenyx Pharmaceutical Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028
Ultragenyx sees rising revenue and analyst support as key drug launch approaches, with potential profitability projected for 2027. 
Via Benzinga
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Ultragenyx Stays On JPMorgan's Focus List As Analyst Highlights Strong Long-Term Positioning
JP Morgan sees strong upside for Ultragenyx, citing setrusumab trial progress and pipeline growth, raising the price target to $117. 
Via Benzinga
Demystifying Ultragenyx Pharmaceutical: Insights From 10 Analyst Reviews
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.